- Barrons.com•16 hours ago
Shares of Sarepta Therapeutics (SRPT) are getting smacked today despite reporting a smaller-than-expected loss. Leerink's Joseph Schwartz and Dae Gon Ha point to Sarepta's inability to "quantify the initial demand" for its recently approved Duchenne Muscular Dystrophy treatment: Sarepta is pleased with the response to Exondys 51 in the marketplace overall, but at just 23 days since approval, believes it is too early to provide metrics or guidance. Sarepta expects to quantify the initial demand/uptake it is seeing after the first full quarter of sales in early January.
- Associated Press•22 hours ago
The Cambridge, Massachusetts-based company said it had a loss of $1.18 per share. Losses, adjusted for stock option expense and non-recurring costs, came to 95 cents per share. The results exceeded Wall ...
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||38.34 x 100|
|Ask||41.80 x 1000|
|Day's Range||40.02 - 45.40|
|52wk Range||8.00 - 63.73|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-7.62|
|Avg Vol (3m)||4,168,232|
|Dividend & Yield||N/A (N/A)|